T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 27-32

  Tembhre, Manoj Kumar ^a   Sharma, Vinod Kumar ^a   Sharma, Alpana ^a   Chattopadhyay, Parthaprasad ^a   Gupta, Somesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Active stable generalized vitiligo; Cytokines; Narrowband ultraviolet B (NB UVB); Regulatory T cells; T helper cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BODY SURFACE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; ULTRAVIOLET B RADIATION; VITILIGO;

ACTIVE/STABLE GENERALIZED VITILIGO; CYTOKINES; GENERALIZED VITILIGO; GV; IFN; IL; INTERFERON; INTERLEUKIN; NARROWBAND ULTRA VIOLET B; NARROWBAND ULTRAVIOLET B (NB-UVB); NB-UVB; REGULATORY T CELL; REGULATORY T CELLS; T HELPER; T HELPER CELLS; TGF; TH; TNF; TRANSFORMING GROWTH FACTOR; TREG; TUMOR NECROSIS FACTOR;

ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MELANOCYTES; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; ULTRAVIOLET RAYS; VITILIGO;

EID: 84878454948     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.05.005     Document Type: Article

References (54)

1. Boissy R.E., Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004, 17:208-214.
2. Cucchi M.L., Frattini P., Santagostino G., Orecchia G. Higher plasma catecholamine and metabolite levels in the early phase of non-segmental vitiligo. Pigment Cell Res 2000, 13:28-32.
3. Lerner A.B., Vitiligo J Invest Dermatol 2013, 32:285-310.
4. Garbelli S., Mantovani S., Palermo B., Giachino C. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?. Pigment Cell Res 2005, 18:234-242.
5. Ongenae K., Van Geel N., Naeyaert J.M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003, 16(2):90-100.
6. Dell'Anna M.L., Picardo M. A review and a new hypothesis for non immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006, 19:406-411.
7. Picardo M., Passi S., Nazzaro-Porro M., et al. Mechanism of antitumoral activity of catechols in culture. Biochem Pharmacol 1987, 36:417-425.
8. Schallreuter K.U. Oxidative stress in the human epidermis. G Ital Dermatol Venereol 2005, 140:505-514.
9. Moretti S., Spallanzani A., Amato L., et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002, 15:87-92.
10. Gauthier Y., Cario Andre M., Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?. Pigment Cell Res 2003, 16:322-332.
11. Zhang X.J., Chen J.J., Liu J.B. The genetic concept of vitiligo. J Dermatol Sci 2005, 39:137-146.
12. Grimes P.E., Ghoneum M., Stockton T., et al. T cell profiles in vitiligo. J Am Acad Dermatol 1986, 14:196-201.
13. Halder R.M., Walters C.S., Johnson B.A., et al. Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J Am Acad Dermatol 1986, 14:733-737.
14. Antelo D.P., Filgueira A.L., Cunha J.M. Reduction of skin-homing cytotoxic T cells (CD8+-CLA+) in patients with vitiligo. Photodermatol Photoimmunol Photomed 2011, 27(1):40-44.
15. Kim J.Y., Do J.E., Ahn K.J., et al. Detection of melanocyte autoantigens reacting with autoantibodies in vitiligo patients by proteomics. J Dermatol Sci 2011, 62(3):202-204.
16. Kemp E.H., Emhemad S., Akhtar S., et al. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol 2011, 20(1):35-40.
17. Waterman E.A., Gawkrodger D.J., Watson P.F., et al. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. J Invest Dermatol 2010, 130(1):230-240.
18. Bettini M., Vignali D.A. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009, 21(6):612-618.
19. Taylor A., Verhagen J., Blaser K., et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulator cells. Immunology 2006, 117(4):433-442.
20. Levings M.K., Bacchetta R., Schulz U., et al. The role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002, 129(4):263-276.
21. Cui J., Shen L.Y., Wang G.C. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991, 97:410-416.
22. Norris D.A., Horikawa T., Morelli J.G. Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994, 7:193-203.
23. Kunz M., Ibrahim S.M. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009, 2009:979258.
24. Yu H.S., Chang K.L., Yu C.L., et al. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, IFN-gamma released by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997, 108:527-529.
25. Grimes P.E., Morris R., Avaniss-Aghajani E., et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004, 51:52-61.
26. Singh S., Singh U., Pandey S.S. Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in vitiligo patients. Indian J Dermatol 2012, 57(1):12-14.
27. Tu C.X., Fu H.W., Lin X.R. Levels of soluble interleukin-2 receptor in the sera and skin fluids of patients with vitiligo. J Dermatol Sci 1999, 21:59-62.
28. Galadari I. Serum levels of the soluble interleukin-2 receptor in vitiligo patients in UAE. Eur Ann Allergy Clin Immunol 2005, 37(3):109-111.
29. Zailaie M.Z. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients. Saudi Med J 2005, 26(7):1085-1091.
30. Caixia T., Hongwen F., Xiran L. Level of soluble interleukin-2 receptor in the sera and tissue fluids of patients with vitiligo. J Dermatol Sci 1999, 21(1):59-62.
31. Franczuk A., Szepietowski J.C., Noworolska A. Serum concentrations of interleukin-2 soluble receptor (IL-2 sR) in patients with vitiligo: relationship with type and extent of the disease. Acta Dermatovenerol Croat 2004, 12(2):71-76.
32. Taher Z.A., Lauzon G., Maguiness S., et al. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol 2009, 161(3):654-659.
33. Basak P.Y., Adiloglu A.K., Ceyhan A.M., et al. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009, 60(2):256-260.
34. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
35. Harrington L.E., Hatton R.D., Mangan P.R., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
36. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., et al. Interleukins 1-beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
37. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
38. Wang C.Q., Cruz-Inigo A.E., Fuentes-Duculan J., et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011, 6(4):e18907.
39. Esmaeili B., Rezaee S.A., Layegh P., et al. Expression of IL-17 and COX2 gene in peripheral blood leukocytes of vitiligo patients. Iran J Allergy Asthma Immunol 2011, 10(2):81-89.
40. Bassiouny D.A., Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2011, 36(3):292-297.
41. Sakaguchi S., Sakaguchi N., Asano M., et al. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 2011, 186(7):3808-3821.
42. Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelation. J Immunol 2003, 71(12):6323-6327.
43. Afzali B., Lombardi G., Lechler R.I., et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007, 148:32-46.
44. Viglietta V., Baecher-Allan C., Weiner H.L., et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199(7):971-979.
45. Kriegel M.A., Lohmann T., Gabler C., et al. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004, 199(9):1285-1291.
46. Ehrenstein M.R., Evans J.G., Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004, 200(3):277-285.
47. Lindley S., Dayan C.M., Bishop A., et al. Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005, 54(1):92-99.
48. Sugiyama H., Gyulai R., Toichi E., et al. Dysfunctional blood and target tissue CD4+CD25+ high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174(1):164-173.
49. Balandina A., Lécart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105(2):735-741.
50. Klarquist J., Denman C.J., Hernandez C., et al. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010, 23(2):276-286.
51. Khan R., Gupta S., Sharma V.K., et al. Circulating levels of T cell cytokines (IL-2, IL-4, IL-17 and TGF-β) in patients with vitiligo. J Am Acad Dermatol 2012, 66(3):510-511.
52. Fiocchi Claudio TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001, 108:523-526.
53. Ulloa L., Doody J., Massague J. Inhibition of transforming growth factor-/SMAD signaling by the interferon-γ/STAT pathway. Nature 1999, 397:710-713.
54. Verrecchia F., Pessah M., Atfi A., et al. Tumor necrosis factor-β [U+F020]inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000, 275:30226-30231.